Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Harmonizing Optimal Strategy for Treatment of Coronary Atherosclerotic Lesions- Registry-based Study on the Effect and Safety of Xience Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerotic Lesions: HOST-Alpine Registry

NCT02845804 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT02845804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02845804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Harmonizing Optimal Strategy for Treatment of Coronary Atherosclerotic Lesions- Registry-based Study on the Effect and Safety of Xience Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerotic Lesions: HOST-Alpine Registry
Lead sponsor
Seoul National University Hospital
Phase
Observational
Overall status
Unknown status
Start date
July 31, 2015
Completion date
July 31, 2021
Enrollment
1,533 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, angina pectoris, coronary artery disease, percutaneous coronary intervention